Welcome to our dedicated page for Orasure Tech SEC filings (Ticker: OSUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OraSure Technologies Inc. filings document the regulatory record of a Nasdaq-listed diagnostics and sample management company. Its Form 8-K reports cover quarterly and annual operating results, Regulation FD presentations, business developments, board changes, and material agreements tied to shareholder and governance matters.
OraSure's proxy materials disclose director elections, executive compensation, board committee structure, shareholder voting matters and governance proposals, including matters related to board classification. The filings also identify the company's common stock listing, capital structure, risk and governance disclosures, and formal records for cooperation agreements, director appointments, resignations and investor communications.
OraSure Technologies director John D. Bertrand submitted a Form 3, which is an initial statement of beneficial ownership for company insiders. This filing is administrative in nature and, in the data provided, does not report any share purchases, sales, or option exercises.
OraSure Technologies director Lelio Marmora reported a routine share disposition related to taxes, not an open-market trade. On the vesting of restricted shares, 28,406 common shares were withheld at $3.02 per share to cover associated tax liabilities.
After this tax-withholding disposition, Marmora directly holds 102,354 shares of OraSure Technologies common stock. This type of transaction is compensation-related and does not represent a discretionary purchase or sale in the open market.
OraSure Technologies director Robert W. McMahon reported a tax-withholding disposition of 22,888 shares of Common Stock at $3.02 per share. These shares were withheld to cover taxes due on the vesting of restricted shares, and McMahon now directly holds 77,031 shares.
OraSure Technologies director Nancy J. Gagliano reported a tax-related share disposition. On the vesting of restricted shares, 21,305 shares of common stock were withheld at a price of $3.02 per share to cover associated tax liabilities. After this withholding, she directly holds 138,949 OraSure common shares.
OraSure Technologies reported first quarter 2026 net revenues of $27.9 million, down 7% from $29.9 million a year earlier, as COVID-19 and risk assessment testing revenue largely disappeared while core revenue declined slightly. GAAP gross margin improved to 42.3% from 41.1%, and non-GAAP gross margin rose to 43.4% from 41.7%, reflecting better mix and cost control.
The company posted a GAAP operating loss of $23.3 million and a GAAP net loss of $22.4 million, compared with losses of $17.8 million and $16.0 million in the prior-year quarter. Diluted GAAP loss per share was $0.32, with non-GAAP diluted loss per share of $0.24. Cash and cash equivalents were $177.0 million as of March 31, 2026 after using $5 million to repurchase about 1.8 million shares. For the second quarter of 2026, OraSure guides total revenues to $27–$30 million and expects non-GAAP gross margin similar to the first quarter.
OraSure Technologies, Inc. files its Annual Report on Form 10-K describing its diagnostics and sample-management businesses, product portfolio, regulatory status, manufacturing footprint and certain 2025 developments.
The report states an aggregate market value of common equity held by non-affiliates of $218,472,693 and 69,126,173 shares outstanding as of February 28, 2026. It discloses the November 2025 acquisition of BioMedomics, 2025 product and pipeline highlights including FDA 510(k) submissions for a CT/NG rapid molecular self-test and a Colli-Pee at-home urine device, ongoing EUA and CLIA statuses for InteliSwab products, BARDA funding for Ebola test development, and continued U.S. manufacturing capacity including a target of more than 100 million tests annually.
OraSure Technologies, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on five key items, including electing three Class II directors and declassifying the Board over three years. Proposals also seek to ratify Grant Thornton LLP, approve executive pay, and amend the Stock Award Plan to add 5,000,000 shares and extend it ten years. The company highlights 2025 net revenue of $115 million, approximately $199 million in cash with no debt, about $19 million in annualized cost savings, and a $40 million repurchase program under which $15 million and 5.3 million shares were repurchased in 2025.
OraSure Technologies Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 3,484,438 shares of Common Stock, representing 5.04% of the class. The filing shows sole voting power for 453,550 shares and sole dispositive power for 3,484,438 shares, and explains holdings include securities held for Vanguard funds and certain affiliates.
OraSure Technologies is soliciting proxies for its virtual 2026 Annual Meeting on June 3, 2026. The Board asks shareholders to: elect three Class II directors; ratify Grant Thornton LLP as auditor; approve advisory executive compensation; approve a 5,000,000-share increase to the Stock Award Plan (raising available shares to 6,982,477); and approve declassification of the Board over three years. The record date for voting is April 10, 2026, when 71,965,612 shares were outstanding. The filing reviews 2025 performance: $115M net revenue, $199M cash, no debt, $15M of share repurchases executed (part of a $40M authorization), and $19M of annualized run-rate cost savings.